Terns Pharmaceuticals (NASDAQ:TERN) Insider Emil Kuriakose Sells 942 Shares of Stock

Terns Pharmaceuticals, Inc. (NASDAQ:TERN) insider Emil Kuriakose sold 942 shares of the stock in a transaction on Wednesday, April 1st. The shares were sold at an average price of $52.75, for a total value of $49,690.50. Following the completion of the sale, the insider owned 105,673 shares of the company’s stock, valued at approximately $5,574,250.75. This represents a 0.88% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Emil Kuriakose also recently made the following trade(s):

• On Friday, January 2nd, Emil Kuriakose sold 1,155 shares of Terns Pharmaceuticals stock. The stock was sold at an average price of $38.57, for a total value of $44,548.35.

Terns Pharmaceuticals Price Performance

Shares of TERN opened at $52.72 on Friday. Terns Pharmaceuticals, Inc. has a 12 month low of $1.87 and a 12 month high of $53.19. The stock’s 50-day moving average is $42.59 and its two-hundred day moving average is $30.32. The stock has a market cap of $6.08 billion, a PE ratio of -51.18 and a beta of -0.37.

Terns Pharmaceuticals (NASDAQ:TERN) last posted its earnings results on Thursday, April 2nd. The company reported ($0.24) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.06. On average, research analysts anticipate that Terns Pharmaceuticals, Inc. will post -1.19 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the company. Commodore Capital LP bought a new stake in shares of Terns Pharmaceuticals in the 3rd quarter valued at approximately $42,807,000. Vestal Point Capital LP bought a new position in Terns Pharmaceuticals during the fourth quarter worth $181,800,000. Avoro Capital Advisors LLC acquired a new position in Terns Pharmaceuticals in the fourth quarter worth $175,740,000. Janus Henderson Group PLC acquired a new position in Terns Pharmaceuticals in the fourth quarter worth $136,496,000. Finally, Capitolis Liquid Global Markets LLC bought a new stake in Terns Pharmaceuticals during the fourth quarter valued at $123,026,000. Institutional investors own 98.26% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on TERN. Mizuho downgraded shares of Terns Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Friday, March 27th. TD Cowen downgraded shares of Terns Pharmaceuticals from a “buy” rating to a “hold” rating and set a $53.00 price target on the stock. in a research note on Thursday, March 26th. Citizens Jmp cut shares of Terns Pharmaceuticals from a “market outperform” rating to a “hold” rating in a research report on Thursday, March 26th. Weiss Ratings restated a “sell (e+)” rating on shares of Terns Pharmaceuticals in a research note on Friday, March 27th. Finally, Leerink Partners began coverage on Terns Pharmaceuticals in a research report on Monday, February 9th. They set an “outperform” rating and a $58.00 target price on the stock. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, seven have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $56.30.

Terns Pharmaceuticals Company Profile

Terns Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing oral small‐molecule therapies for the treatment of chronic liver diseases and other serious conditions. The company’s research and development efforts center on novel mechanisms of action designed to address the underlying causes of progressive liver disorders, including inflammation, fibrosis and metabolic dysregulation. By advancing targeted compounds that can be administered orally, Terns aims to offer patients more convenient and effective treatment options compared to injectable or biologic therapies.

The company’s pipeline features several candidates in various stages of preclinical and clinical evaluation.